Background: currently one of the major challenges facing clinical guidelines is multimorbidity. Current guidelines are not designed to consider the cumulative impact of treatment recommendations on people with several conditions, nor to allow comparison of relative benefits or risks. This is despite the fact that multimorbidity is a common phenomenon. Objective: to examine the extent to which National Institute of Health and Clinical Excellence (NICE) guidelines address patient comorbidity, patient centred care and patient compliance to treatment recommendations. Methods: five NICE clinical guidelines were selected for review (type-2 diabetes mellitus, secondary prevention for people with myocardial infarction, osteoarthritis, chronic obstructive pulmonary disease and depression) as these conditions are common causes of comorbidity and the guidelines had all been produced since 2007. Two authors extracted information from each full guideline and noted the extent to which the guidelines accounted for patient comorbidity, patient centred care and patient compliance. The cumulative recommended treatment, follow-up and self-care regime for two hypothetical patients were then created to illustrate the potential cumulative impact of applying single disease recommendations to people with multimorbidity.
Introduction
Clinical guidelines systematically bring together evidence regarding a single condition or group of related conditions, and provide recommendations for patient management based on the evidence where it exists and consensus where it does not. The implementation of clinical guideline recommendations reduces practice variation, and is associated with reduced deaths and hospitalisations [1] . These improvements have been achieved by linking guideline recommendations with financial incentives, such as the quality outcomes framework. Importantly, existing clinical guidelines largely focus on single diseases, and are usually based on evidence from highly selected populations who may not be typical of the actual population with the condition.
Currently one of the major challenges facing clinical guidelines is multimorbidity. Multimorbidity has been defined as 'the co-occurrence of multiple chronic or acute diseases and medical conditions within one person' [2] . Current guidelines are not designed to consider the cumulative impact of treatment recommendations on people with several conditions, nor to allow the comparison of relative benefits or risks. This is despite the fact that multimorbidity is a common phenomenon, and in older people is the norm [3] [4] [5] . Indeed, Uijen et al. [3] noted that 55% of Dutch people aged 75 and over have four or more chronic conditions. This paper examines the application of National Institute of Health and Clinical Excellence (NICE) guidelines to people with multimorbidity and the implications for the creation of evidence and future guideline development.
Limitations of existing clinical guidelines
Existing guidelines are usually based on evidence from clinical trials carried out in relatively narrow subsets of the population. Older people have historically been systematically excluded from clinical trials, even though older people usually have the highest prevalence of chronic disease and are therefore the most likely targets of guideline recommendations [6, 7] . Trials also often exclude people with significant comorbidity, further narrowing the population studied [6, 7] . Key clinical trials in heart failure would only have included 13-25% of people with diagnosed heart failure in the community [8] , with the corresponding figure for chronic obstructive pulmonary disease (COPD) being 10% [9] . Overall, 81% of randomised controlled trials published in high-impact journals excluded patients with medical comorbidities [6] . Ensuring the internal validity of trials is critical, but the external validity or generalisability of much current evidence is often relatively weak [10] .
Driven by the nature of evidence and reflecting current health-care organisation, guidelines usually focus on a single condition, although most people with chronic disease have multiple conditions, and the majority of older people are multimorbid [3-5, 11, 12] . In 2005 Boyd et al. [13] examined the applicability of US clinical guidelines to older individuals with several comorbid diseases. The study reviewed clinical guidelines for nine chronic conditions to determine whether they adequately addressed the care needs of older patients with multiple comorbid diseases. The authors found that clinical guidelines rarely addressed comorbidity, and adherence to guideline recommendations in caring for an older person with multimorbidity would often lead to complex and sometimes contradictory drug and self-care regimes [13] . However, it is unclear whether the same applies in countries where guideline development is more co-ordinated, and the US study only examined guidelines for physical conditions despite physical-mental health comorbidity being common [3] .
Methods
Applying NICE guidelines to people with multimorbidity We examined the extent to which recent UK clinical guideline recommendations for five common conditions addressed care for older people, comorbidity and patient-centred care. The guidelines selected were for type 2 diabetes mellitus, secondary prevention in people with previous myocardial infarction (MI), osteoarthritis, chronic COPD and depression (two guidelines including one for managing depression in people with chronic physical problems) [14] [15] [16] [17] [18] [19] . These conditions were chosen because they are common causes of morbidity and a NICE clinical guideline had been published in the past 5 years for each. The majority of people with these conditions will have significant comorbidity (71% of people with diabetes are multimorbid, 92% with coronary heart disease, 82% with osteoarthritis, 83% with COPD and 64% with depression) [2] .
L.H. and B.G. extracted information from each full guideline and quick reference guide when available, which summarise the recommendations and are the documents most likely to be used by clinicians. We examined whether and how recommendations gave specific advice about care for older people or those with comorbidities, advice on providing patient-centred care by accounting for patient choice and preferences, and advice on promoting adherence to treatment recommendations. These criteria were selected as guidelines have been noted in previous studies to be limited in relation to age-specific and multimorbid-specific clinical recommendations, and in providing information about how patient-centred care can be achieved while following guidelines [13, 20] . In addition, despite patient adherence being recognised as a major problem, particularly in multimorbid patients, there has been limited reference on how this can be promoted in guideline recommendations [5, 13] . The authors wished to assess if UK-based guidelines had similar limitations or provided more comprehensive guidance for clinicians.
The authors noted the extent to which guidelines discussed these criteria and categorised this as none, minimal (criteria specifically noted on ≤2 occasions), moderate (criteria specifically noted on 3-5 occasions) or extensive (criteria specifically noted ≥5 occasions).
For each guideline, recommendations for chronic management were summarised for drug treatment, self-care and health service follow-up. The cumulative recommended treatment, follow-up and self-care regime for two hypothetical patients was then created to illustrate the potential cumulative impact of applying single disease recommendations to people with multimorbidity. These patients were Mrs A, a 78-year-old woman with all five conditions at mild-to-moderate severity, and Mr B, a 75-year-old man with two conditions (type 2 diabetes mellitus and COPD) at mild-to-moderate severity.
Results
Do the guidelines explicitly address age, comorbidity and patient-centred care?
All of the guidelines consider older patients to varying degrees, although usually via general statements suggesting that clinicians should consider individual drug characteristics and prescribe age-adjusted doses of relevant medications. More specific advice ranged from minimal mention of antidepressant choice in older people in the depression guideline to moderate discussion of particular recommendations in other guidelines, such as that age should not influence the offer of cardiac rehabilitation after MI. No guideline explicitly commented on the quality of the evidence in older people, or on the generalisability of trial evidence (Table 1) .
Comorbidity was inconsistently accounted for in the guidelines, usually without detailed discussion. Comorbidity was most extensively addressed in the depression guidelines, which provided comprehensive advice on management in the presence of a physical condition with functional limitation and on important interactions of antidepressant drugs. Two of the physical disease guidelines provided extensive discussion for a few topics (holistic assessment in osteoarthritis and the promotion of uptake of cardiac rehabilitation in people with other conditions), but otherwise only relatively minimal comment in relation to particular treatments. Apart from the MI guideline, cross-referencing to other guidelines for important comorbidities was uncommon, and no information was provided on the relative risks and benefits of the different treatments recommended.
All the guidelines examined had a generic introduction emphasising the importance of tailoring treatment to patients' needs and preferences. However, this generic advice was very similar across guidelines, and provided limited disease-specific recommendations for achieving patient-centred care. In addition to the generic introduction, the depression guideline extensively discussed accounting for individual preference, whereas the physical disease guidelines varied from some discussion of patient preference in relation to particular drugs (oral hypoglycaemics in the diabetes guideline) through general advice on clearly communicating risks and benefits of treatment (osteoarthritis) to no explicit discussion (MI and COPD).
In terms of adherence to treatment recommendations, the depression guideline had a moderate amount of explicit discussion of ensuring adherence to antidepressant drugs by involving patients in the decision to initiate medication, and assessing adherence in non-responders. The physical disease guidelines ranged from moderate discussion in relation to particular topics (cardiac and pulmonary rehabilitation, inhaler technique, exercise) to no explicit discussion (diabetes), although research into the relationship between treatment regime complexity and adherence was recommended by the guidelines for osteoarthritis, secondary prevention of MI and type 2 diabetes mellitus (Table 1) .
Overall, there was limited accounting for age, comorbidity, patient centredness and adherence in the recommendations made by guidelines, with the depression guideline providing significantly more comprehensive guidance than the physical disease guidelines which typically only discussed these issues in relation to particular recommendations. It was unclear why these recommendations were prioritised since, for example, adherence to blood pressure lowering medication in type 2 diabetes seems as likely to be problematic as adherence to oral hypoglycaemics.
Applying the guidelines to hypothetical patients
We identified guideline recommendations applicable to two patients:
• Mrs A: A 78-year-old woman with previous MI, type 2 diabetes, osteoarthritis, COPD and depression.
• Mr B: A 75-year-old man with type 2 diabetes mellitus and COPD.
These were used to derive a treatment plan that included prescribed drugs, self-care tasks and recommended healthcare follow-up. care/lifestyle alterations, with others recommended under some circumstances. As well as any unplanned appointments, she would be expected to attend 8-10 routine primary care appointments for her physical conditions, 4-6 GP appointments and 8-30 psychosocial intervention appointments for her depression, and multiple appointments for smoking cessation support and pulmonary rehabilitation if she chose to accept a referral. The guideline recommendations are summarised in Table 2 .
Mr B: 75-year-old man with two conditions NICE guidelines recommend Mr B be prescribed five medications as a minimum, with up to eight other drugs routinely recommended depending on the intermediate outcome control, symptoms and progression of disease. He would be advised to routinely engage in six self-care/lifestyle alterations, with others recommended under some circumstances (e.g. complications associated with diabetes). As well as any unplanned appointments, he would be expected to attend five to eight routine primary care appointments for his physical conditions, three to five GP appointments and multiple appointments for smoking cessation support and pulmonary rehabilitation if he chose to accept a referral. The guideline recommendations are summarised in Table 3 . Annual retinal screening by quality assured digital retinal photography programme 3-6 monthly monitoring of HbA1c and 4-6 monthly monitoring of blood pressure One-off pneumococcal and annual influenza immunisation Offer referral to smoking intensive support service Offer referral for pulmonary rehabilitation a Additional drugs routinely recommended for more severe disease, notably if poor control of blood pressure (up to three additional drugs), HbA1c control (up to three additional drugs) and/or lipids (up to one additional drug); poor pain control in osteoarthritis on simple analgesia (potentially multiple drug classes); persistent depression despite initial treatment (switching of antidepressant medication rather than addition); progressive symptoms or reduced lung function in COPD (up to two additional inhaled drugs). b GP review 2 weeks after diagnosis, then every 2-4 weeks for 3 months, then monthly if stable. c Individual guided self-help programme or computerised cognitive behavioural therapy (CBT), supported physical activity or group CBT. d Multiple elements requiring a stand-alone and often extended appointment and/or consultation with more than one professional.
Discussion
Cumulative impact of applying NICE guidelines Despite examining guidelines produced by a single national organisation (NICE), our findings are consistent with a previous study examining US guidelines for physical disease [13] , and are likely to apply in other countries. The cumulative impact of applying all five guidelines for Mrs A and two guidelines for Mr B was considerable, even when only recommendations for mild-to-moderate disease were considered. The treatment, selfcare and follow-up regime recommended was highly complex, and would be challenging to adhere to because of the high treatment burden implied [21] . The guidelines studied did not explicitly address the treatment burden or adherence, nor provide any guidance on the relative risks and benefits of the many treatments recommended. Although NICE full evidence summaries do provide information on the risks and benefits of treatment, few clinicians will have the time or expertise to read and interpret these documents, and the information is not consistently presented to facilitate comparison. High treatment burden including polypharmacy is not intrinsically inappropriate, but particularly in people with physical frailty or limited life expectancy, better guidance on the relative risks and benefits of different treatments, and the likely time to benefit would assist clinical decision-making. Similarly, where patients have strong preferences about limiting treatment burden, particularly when treatments are primarily preventive rather than for symptoms, then such guidance would help prioritise decision-making.
Implications for the creation of evidence and future guideline development
Multimorbidity is already common, and will become more so as the population ages and survival from acute disease improves [4, 12] . Multimorbidity is strongly associated with higher mortality, poorer quality of life and functional status, and higher rates of health service use including emergency hospital admission [22, 23] . Better management of people with multimorbidity is therefore a key challenge for health-care systems internationally. Clinical guidelines have an important role to play in meeting this challenge, but are constrained by the evidence on which recommendations are based and by their current design [1, 13, 24] . Ultimately, it will always remain the clinician's role to assimilate and review the bodies of evidence relevant to the patient in front of them and then exert their clinical judgement. Concerns have been voiced about linking guideline recommendations with targets/financial incentives and whether this might result in prescriptions being made which materially benefit the prescriber but may not be in the best interests of particular patients [25] . Clearly, clinicians do not wish to be in a situation where they have to defend every deviation from guideline recommendations in order to achieve financial targets. Nor do they wish to be the subject of complaints based around their failure to follow guideline recommendation to the letter [26, 27] .
Although there never will be perfect evidence for all situations, the generalisability of single disease research could be improved by targeted examination of the efficacy of very commonly prescribed treatments in more representative multimorbid and older populations [7, 13, 24] , and by significantly extending the scope and volume of existing research that focuses on the care for people with commonly comorbid conditions, such as studies of the collaborative management of depression, coronary heart disease and diabetes [28] . Guidelines could be made more useful in supporting the care for people with multimorbidity in a number of ways (Table 4) [13, 20, 24] . Firstly, existing guidelines should explicitly cross-reference each other when recommendations are synergistic or contradictory, and identify high-risk interactions between recommended treatments and other commonly prescribed drugs. The depression guideline provides a potential model in its provision of a table of drug and disease interactions for commonly used antidepressants. Secondly, clinical guidelines should include a small number of specific patient vignettes for common combinations of comorbidity seen in clinical practice. This may help avoid some of the issues associated with 'adding-up' clinical recommendations from different guidelines. Furthermore, these patient examples may also provide an opportunity for the guideline to list specific advice for practitioners to consider as the patient ages relating, for example, to drug dose or class. Thirdly, action to increase the participation of older people in clinical trials would make it more likely that the distillation of research evidence that forms guidelines had relevance to people with multimorbidity [28] .
Current guidelines are largely paper based, and focus on individual diseases in isolation. In caring for people with multimorbidity, what would be more helpful would be a guideline that summarised and cross-referenced recommendations relevant to a particular patient from all single-disease guidelines, identifying when recommendations are synergistic, potentially risky or contradictory. Additionally, providing summarised and comparable information about the relative benefits and risks of different recommended treatments would help inform prioritisation, although in the face of such complexity, clinical judgement and careful accounting for patient choice preferences will always be critical. Internetbased platforms make delivering such guidelines for people feasible, although there are considerable challenges to their production. Although there will often be limited evidence to underpin explicit comparison of different treatments, existing NICE guideline methodology already uses modelling and expert consensus to address evidence gaps, and these could be applied to this problem. Research is needed to identify the best way to create such guidelines for people from existing guidelines for diseases and to evaluate their usability and usefulness to clinicians and patients [13, 23] .
Conclusion
Clinical guidelines have played an important role in improving health care for people with long-term conditions. However, in people with multimorbidity current guideline recommendations rapidly cumulate to drive polypharmacy, without providing guidance on how best to prioritise recommendations for individuals in whom the treatment burden will sometimes be overwhelming. Such prioritisation will always require the exercise of clinical judgement and meaningful engagement with patient preferences. Developing guidelines for people rather than guidelines for diseases will better ensure that treatment is in the individual's best interests.
Key points
• The use of clinical guidelines in health-care services has helped to reduce practice variation, deaths and hospitalisations • Clinical guidelines are known to be limited in their focus on single diseases and the evidence which these guidelines are based upon apply only to subsets of the population • This study showed that explicitly following clinical guidelines for two hypothetical patients with physical and mental health comorbidities produced complex treatment regimes with a significant risk of adverse drug reactions.
• To make clinical guidelines more applicable to patients with comorbidity, future clinical guidelines should provide practical examples of how patient-centred care can be achieved for a disease process. Attempts should be made to integrate guidelines for similar disease processes.
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